Department of Nephrology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, Hubei, China.
Medical School, Jianghan University, Wuhan, 430056, Hubei, China.
Int Urol Nephrol. 2022 Nov;54(11):2959-2967. doi: 10.1007/s11255-022-03234-0. Epub 2022 May 17.
Chronic kidney disease (CKD) patients have high levels of inflammatory mediators. These inflammatory mediators contribute to the increased risk of cardiovascular events and all-cause mortality. Platelet-lymphocyte ratio (PLR) has recently been recognized as a novel inflammatory marker and has been shown to be associated with the prognosis in CKD patients. However, the quality of these studies varies and their results are controversial. The purpose of this meta-analysis was to investigate the relationship between PLR and all-cause mortality in CKD patients.
A systematic literature search of PubMed, EMBASE, CENTRAL and ISI Web of Science was conducted. The databases were searched from their inception dates up to the latest issue (31 October 2021). Two reviewers independently searched the databases and screened studies. Data were extracted using a standardized collection form. Meta-analysis was performed to compare PLR values between CKD and non-CKD patients, and to investigate the association between PLR and all-cause mortality in CKD patients. This meta-analysis is reported in adherence to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
A total of 11 studies involving 4244 participants were selected. The pooled data indicated that PLR values were significantly higher in CKD patients than non-CKD controls (weighted mean difference = 21.6, 95% CI 17.39-25.81, p < 0.01), and PLR is associated with an increased risk of all-cause mortality in CKD patients (hazard ratio = 2.49, 95% CI 1.78-3.49, p < 0.01).
Patients with CKD have higher PLR values compared to non-CKD patients. Meanwhile, PLR values were highly associated with all-cause mortality in CKD patients. PLR is a valid predictor as a clinically accessible indicator for patients with CKD.
慢性肾脏病（CKD）患者体内的炎症介质水平较高。这些炎症介质会增加心血管事件和全因死亡率的风险。血小板-淋巴细胞比值（PLR）最近被认为是一种新的炎症标志物，并且已经被证实与 CKD 患者的预后相关。然而，这些研究的质量参差不齐，其结果存在争议。本荟萃分析的目的是探讨 PLR 与 CKD 患者全因死亡率之间的关系。
系统检索了 PubMed、EMBASE、CENTRAL 和 ISI Web of Science 数据库，检索时间从建库至 2021 年 10 月 31 日。两名评审员独立检索数据库并筛选研究。使用标准化的采集表提取数据。荟萃分析比较了 CKD 患者和非 CKD 患者的 PLR 值，并探讨了 PLR 与 CKD 患者全因死亡率之间的关系。本荟萃分析按照系统评价和荟萃分析的首选报告项目（PRISMA）进行报告。
共纳入了 11 项涉及 4244 名参与者的研究。汇总数据表明，与非 CKD 对照组相比，CKD 患者的 PLR 值显著升高（加权均数差=21.6，95%置信区间 17.39-25.81，p<0.01），并且 PLR 与 CKD 患者全因死亡率的增加相关（风险比=2.49，95%置信区间 1.78-3.49，p<0.01）。
与非 CKD 患者相比，CKD 患者的 PLR 值更高。同时，PLR 值与 CKD 患者的全因死亡率高度相关。PLR 是 CKD 患者一种有效的预测指标，是一种临床可及的指标。
